公开(公告)号：US20110136173A1

公开(公告)日：2011-06-09

申请号：US12961751

申请日：2010-12-07

Applicant: ANDREAS PLÜCKTHUN ,  ANNEMARIE HONEGGER ,  JÖRG WILLUDA

Inventor： ANDREAS PLÜCKTHUN ,  ANNEMARIE HONEGGER ,  JÖRG WILLUDA

IPC: C12P21/02 ,  C07H21/00

CPC classification number: C07K16/00 ,  A61K47/6813 ,  A61K47/6819 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6825 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6877 ,  A61K51/1045 ,  A61K51/1087 ,  A61K2039/505 ,  C07K16/06 ,  C07K16/28 ,  C07K16/30 ,  C07K16/465 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

Abstract: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.

Abstract translation: 本发明涉及稳定嵌合免疫球蛋白或免疫球蛋白片段的方法。 此外，本发明还提供了稳定的抗EGP-2 scFv片段。

公开(公告)号：US07858088B2

公开(公告)日：2010-12-28

申请号：US11969059

申请日：2008-01-03

Applicant: Andreas Plückthun ,  Annemarie Honegger ,  Jörg Willuda

Inventor： Andreas Plückthun ,  Annemarie Honegger ,  Jörg Willuda

IPC: A61K39/395 ,  A61P31/00 ,  C07K16/18

CPC classification number: C07K16/00 ,  A61K47/6813 ,  A61K47/6819 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6825 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6877 ,  A61K51/1045 ,  A61K51/1087 ,  A61K2039/505 ,  C07K16/06 ,  C07K16/28 ,  C07K16/30 ,  C07K16/465 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

Abstract: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.

Abstract translation: 本发明涉及稳定嵌合免疫球蛋白或免疫球蛋白片段的方法。 此外，本发明还提供了稳定的抗EGP-2 scFv片段。

公开(公告)号：US20050037005A1

公开(公告)日：2005-02-17

申请号：US10943442

申请日：2004-09-17

Applicant: Seth Lederman ,  Leonard Chess ,  Michael Yellin

Inventor： Seth Lederman ,  Leonard Chess ,  Michael Yellin

IPC: G01N33/50 ,  A61K35/76 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61K49/00 ,  A61K51/10 ,  A61P3/10 ,  A61P5/14 ,  A61P7/04 ,  A61P7/06 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P29/00 ,  A61P31/14 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/09 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/02 ,  C12R1/91 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  A61K47/6849 ,  A61K51/1039 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/70575 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2319/00 ,  C12N5/0694 ,  Y02A50/401 ,  Y10S514/885

Abstract: This invention provides a monoclonal antibody which specifically recognizes and forms a complex with a protein located on the surface of activated T cells and thereby inhibits T cell activation of B cells. This invention also provides the monoclonal antibody 5c8 (ATCC Accession No. ______). This invention provides a human CD4− T cell leukemia cell line designated D1.1 (ATCC Accession No. ______) capable of constitutively providing contact-dependent helper function to B cells. This invention also provides an isolated protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. This invention further provides an isolated, soluble protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells.

Abstract translation: 本发明提供了一种单克隆抗体，其特异性识别并与位于活化T细胞表面的蛋白质形成复合物，从而抑制B细胞的T细胞活化。 本发明还提供单克隆抗体5c8（ATCC登录号______）。 本发明提供了能够组成型地向B细胞提供接触依赖性辅助功能的人类CD4 + T细胞白血病细胞系D1.1（ATCC登录号______）。 本发明还提供了从活化的T细胞表面分离的蛋白质，其中所述蛋白质对B细胞的T细胞活化是必需的。 本发明还提供了从活化的T细胞的表面分离的可溶性蛋白质，其中所述蛋白质对B细胞的T细胞活化是必需的。

公开(公告)号：US20040043029A1

公开(公告)日：2004-03-04

申请号：US10336672

申请日：2003-01-02

Applicant: Bristol-Myers Squibb Company

Inventor： Ingegerg Hellstrom ,  Karl Erik Hellstrom ,  Kim Folger Bruce ,  George J. Schreiber

IPC: A61K039/395 ,  C12N005/06 ,  C07K016/30

CPC classification number: G01N33/57484 ,  A61K38/00 ,  A61K47/6809 ,  A61K47/6811 ,  A61K47/6829 ,  A61K47/6851 ,  A61K49/0058 ,  A61K51/1045 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/415 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2319/00 ,  C12N15/10

Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(abnull)2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(abnull)2-LysPE40 and ChiBR96 Fabnull-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

Abstract translation: 本发明涉及与人癌细胞反应的新型抗体，抗体片段和抗体缀合物和单链免疫毒素。 更具体地，本发明的抗体，缀合物和单链免疫毒素包括：鼠单克隆抗体BR96; 人/鼠嵌合抗体，ChiBR96; BR96的F（ab'）2片段; ChiBR96-PE，ChiBR96-LysPE40，ChiBR96F（ab'）2-LysPE40和ChiBR96 Fab'-LysPE40缀合物和重组BR96sFv-PE40免疫毒素。 这些分子与人类癌症表面的细胞膜抗原反应。 BR96抗体及其功能等同物对癌细胞显示出高度的选择性，并具有介导抗体依赖性细胞毒性和补体依赖性细胞毒活性的能力。 此外，本发明的抗体内在于它们结合的癌细胞内，因此特别可用于治疗应用，例如作为抗体药物或抗体 - 毒素缀合物的抗体组分。 抗体还具有独特的特征，因为当以指定浓度以未修饰的形式使用时，它们是细胞毒性的。

公开(公告)号：US20020146846A1

公开(公告)日：2002-10-10

申请号：US09971543

申请日：2001-10-04

Inventor： Andreas Pluckthun ,  Annemarie Honegger ,  Jorg Willuda

IPC: G01N033/543 ,  G06F019/00 ,  G01N033/48 ,  G01N033/50

CPC classification number: C07K16/00 ,  A61K47/6813 ,  A61K47/6819 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6825 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6877 ,  A61K51/1045 ,  A61K51/1087 ,  A61K2039/505 ,  C07K16/06 ,  C07K16/28 ,  C07K16/30 ,  C07K16/465 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

Abstract: The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.

Abstract translation: 本发明涉及稳定嵌合免疫球蛋白或免疫球蛋白片段的方法。 此外，本发明还提供了稳定的抗EGP-2 scFv片段。

公开(公告)号：US5869045A

公开(公告)日：1999-02-09

申请号：US459354

申请日：1995-06-02

Applicant: Ingegerg Hellstrom ,  Karl Erik Hellstrom ,  Kim Folger Bruce ,  George J. Schreiber

Inventor： Ingegerg Hellstrom ,  Karl Erik Hellstrom ,  Kim Folger Bruce ,  George J. Schreiber

IPC: A61K38/00 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  C07K14/415 ,  C07K16/30 ,  C12N15/10 ,  G01N33/574 ,  A61K39/395 ,  C07K16/00

CPC classification number: A61K47/48407 ,  A61K47/48415 ,  A61K47/48484 ,  A61K47/48569 ,  A61K49/0058 ,  A61K51/1045 ,  A61K51/1087 ,  C07K14/415 ,  C07K16/30 ,  C12N15/10 ,  G01N33/57484 ,  A61K2123/00 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2319/00

Abstract: The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

Abstract translation: 本发明涉及与人癌细胞反应的新型抗体，抗体片段和抗体缀合物和单链免疫毒素。 更具体地，本发明的抗体，缀合物和单链免疫毒素包括：鼠单克隆抗体BR96; 人/鼠嵌合抗体，ChiBR96; BR96的F（ab'）2片段; ChiBR96-PE，ChiBR96-LysPE40，ChiBR96F（ab'）2-LysPE40和ChiBR96 Fab'-LysPE40缀合物和重组BR96sFv-PE40免疫毒素。 这些分子与人类癌症表面的细胞膜抗原反应。 BR96抗体及其功能等同物对癌细胞显示出高度的选择性，并具有介导抗体依赖性细胞毒性和补体依赖性细胞毒活性的能力。 此外，本发明的抗体内在于它们结合的癌细胞内，因此特别可用于治疗应用，例如作为抗体药物或抗体 - 毒素缀合物的抗体组分。 抗体还具有独特的特征，因为当以指定浓度以未修饰的形式使用时，它们是细胞毒性的。

公开(公告)号：US5677427A

公开(公告)日：1997-10-14

申请号：US457138

申请日：1995-06-01

Applicant: David M. Goldenberg ,  Hans J. Hansen

Inventor： David M. Goldenberg ,  Hans J. Hansen

IPC: A61K39/395 ,  A61K45/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/16 ,  A61K51/00 ,  A61K51/10 ,  A61P29/00 ,  A61P31/04 ,  A61K49/02

CPC classification number: A61K51/109 ,  A61K47/48369 ,  A61K47/48546 ,  A61K47/48669 ,  A61K47/48676 ,  A61K49/16 ,  A61K51/1087 ,  A61K51/1093 ,  A61K2121/00 ,  A61K2123/00

Abstract: A chimeric antibody-agent conjugate for targeting foci of leukocyte accretion comprises a recombinant chimera having an antigen-binding hypervariable region which binds specifically to granulocytes, and a constant region of a human immunoglobulin having an Fc portion with high affinity for receptors on human mononuclear lymphoid cells, said chimera being conjugated to at least one diagnostic agent or therapeutic agent. A method for targeting an imaging or therapy agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above chimeric anti-leukocyte conjugate.

公开(公告)号：US20240207461A1

公开(公告)日：2024-06-27

申请号：US18556577

申请日：2022-04-21

Applicant: NIHON MEDI-PHYSICS CO., LTD. ,  Sumitomo Pharma Co., Ltd.

Inventor： Shota KOMOTO ,  Naoaki YAMADA

IPC: A61K51/10 ,  A61K31/315 ,  A61K31/585 ,  A61K31/635

CPC classification number: A61K51/1087 ,  A61K31/315 ,  A61K31/585 ,  A61K31/635

Abstract: The present invention aims to provide a Actinium-225-labeled anti-MUC5AC humanized antibody that is superior in the specificity for mucin subtype 5AC (MUC5AC) and accumulation in tumor, and shows reduced renal toxicity. The present invention relates to a conjugate of a chelating agent chelated with Actinium-225 and an antibody, wherein the antibody is a humanized antibody that specifically binds to mucin subtype 5AC and has a heavy chain variable region consisting of the amino acid sequence shown in any of SEQ ID NOs: 1 to 4, and a light chain variable region consisting of the amino acid sequence shown in any of SEQ ID NOs: 5 to 8.

公开(公告)号：US20230391851A1

公开(公告)日：2023-12-07

申请号：US18454967

申请日：2023-08-24

Applicant: The Binding Site Group Limited

Inventor： Gregg Wallis ,  Jamie Ashby ,  Stephen Harding

IPC: C07K16/06 ,  G01N33/68 ,  C07K16/00 ,  A61K47/68 ,  A61K51/10

CPC classification number: C07K16/065 ,  G01N33/6854 ,  C07K16/00 ,  G01N33/6857 ,  A61K47/6877 ,  A61K51/1087 ,  A61K51/1093 ,  C07K2317/94 ,  A61K2123/00 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/624

Abstract: A method for analyzing protein(s) in a sample using an immunoassay kit includes creating protein-reducing and/or protein-denaturing conditions by contacting the sample with a reducing and/or denaturing agent provided in the immunoassay kit, to provide a partially or fully denatured protein population. One or both of a presence and an amount of one or more protein-associated analytes are determined under the created protein-reducing and/or protein-denaturing conditions by contacting the partially or fully denatured protein population with one or more specific antibodies or binding fragments thereof provided in the immunoassay kit. The one or more specific antibodies or binding fragments thereof include one or more chemically-introduced non-disulfide cross-links between at least one heavy chain or binding fragment thereof and at least one light chain or binding fragment thereof.

公开(公告)号：US20180193479A1

公开(公告)日：2018-07-12

申请号：US15614468

申请日：2017-06-05

Applicant: City of Hope

Inventor： John C. Williams ,  David A. Horne ,  Yuelong Ma ,  Heng Wei Chang ,  Joshua Michael Donaldson ,  Cindy Zer ,  Krzysztof Bzymek ,  Kendra Nicole Avery ,  Jun Xie

IPC: A61K47/68 ,  A61K51/10 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K47/6811 ,  A61K47/66 ,  A61K47/6813 ,  A61K47/6851 ,  A61K47/6877 ,  A61K47/6897 ,  A61K51/1087 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K2299/00 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.